This could indicate that the source of high serum levels of osteopontin is related to micrometastatic disease and extracellular matrix remodeling at the metastatic niche, rather than leakage of osteopontin to the blood stream from the primary tumor. This evidence concerns the gene SPP1 and neoplasm.